An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Condition:   Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation Interventions:   Drug: Afatinib;   Drug: Paclitaxel Sponsor:   AZ-VUB Recruiting

Source: ClinicalTrials.gov - January 21, 2019 Category: Research Source Type: clinical trials